AGRA
Acellular Growth Retardation Ability
Determination of the state of the humoral immune system in patients with liver disease.
Predicting Severe Infections in Patients with Liver Disease
The Challenge
Liver cirrhosis is a leading cause of morbidity and mortality worldwide and is frequently associated with severe bacterial infections. Patients with advanced liver disease have a significantly impaired immune system, making them particularly vulnerable to life-threatening complications such as sepsis, acute kidney injury, and acute-on-chronic liver failure.
These infections often result in prolonged hospitalizations, intensive care admissions, and high mortality rates. Despite this substantial clinical burden, physicians currently have limited tools to identify patients at the greatest risk before severe infections occur.
Our Innovation
AGRA is a novel biomarker-based approach designed to assess immune dysfunction and identify patients at increased risk of severe bacterial infections.
By measuring specific immune-related biomarkers, AGRA enables a more precise evaluation of the patient’s immune status and provides valuable insights into infection susceptibility. This information can support risk stratification, earlier clinical intervention, and more personalized patient management.
Solution
AGRA is a novel biomarker assay that provides a functional assessment of immune competence and infection susceptibility. By identifying patients at increased risk of severe bacterial infections before clinical deterioration occurs, AGRA supports earlier intervention, improved risk stratification, and more personalized patient management. Initially developed for liver cirrhosis, the technology may also be applicable to other chronic diseases characterized by immune dysfunction.
Potential Impact
AGRA has the potential to transform the management of patients with liver cirrhosis by enabling proactive identification of individuals at high risk of serious infections before clinical deterioration occurs.
Beyond liver cirrhosis, the technology may also be applicable to other chronic diseases characterized by immune dysfunction and elevated infection risk, supporting improved patient outcomes while reducing healthcare burden and associated costs.
Key Benefits
- Early identification of patients at risk of severe bacterial infections
- Improved risk stratification and clinical decision-making
- Support for preventive and personalized treatment strategies
- Potential reduction in infection-related complications, hospitalizations, and mortality
- Broad applicability across chronic diseases associated with immune impairment